Ventripoint Welcomes Dr. Jose Banchs as New Clinical Advisor
Toronto, Ontario – TheNewswire – April 27, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to have Dr. Jose Banchs join its Board of Clinical Advisors.
Dr. Banchs has been involved with Ventripoint’s development for the past few years and will now take on a leadership role for clinical development. Dr. Banchs is the current Director of Echocardiography at the University of Colorado’s Anschutz Medical Campus as well as a Professor of Medicine in the Cardiology Division at the University of Colorado. He is a diplomate of the American Board of Internal Medicine in Cardiovascular Disease and the National Board of Echocardiography.
Dr. Banchs has been a consultant for numerous organizations across the United States over the years. His extensive experience and excellence in both research and teaching has earned him many honors and awards. He has been recognized as TX Top Doctor 2020 and 2019, received the Faculty Teacher of the Year Award for multiple years in a row and in 2021 was the recipient of the ASE Meritorious Service Award.
Dr. Banchs has an extensive list of published work within the biomedical field, such as research articles, book chapters, and abstracts. Based on 2018 data, there are 2,380 deaths from cardiovascular disease each day in the US. Ventripoint aims to bring a faster and reliable diagnostic tool for cardiac disease with the help of experts like Dr. Banchs. Dr. Banchs will bring the insight he has gained as a top doctor in the cardiology field as well as the latest research in cardiology developments to Ventripoint.
“I am excited to join Ventripoint clinical advisory board at a time when there is great progress and innovation in the area of cardiac imaging. I believe Ventripoint’s Knowledge Based Reconstruction (KBR) technology is unique and provides the imaging clinicians with an unparallel escalation of precision and overall imaging quality at their fingertips. The concept and implementation are revolutionary, improves our interpretation confidence and will ultimately help improve our patient care.” stated Dr. Banchs.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Dr. George Adams
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.